Experience

Davis Polk advised NatWest Group plc, a public limited company incorporated under the laws of Scotland, in connection with its SEC-registered shelf takedown of £1 billion aggregate…

Davis Polk advised the sales agents in connection with an SEC-registered at-the-market offering by BioNTech SE of its ordinary shares represented by American depositary shares for up to an…

Davis Polk advised the sales agent in connection with the establishment of an SEC-registered at-the-market offering program by Affimed N.V. of up to $75 million gross sales price of…

Davis Polk advised the underwriters in connection with an SEC-registered offering of $700 million aggregate principal amount of 3.750% notes due 2030 by AngloGold Ashanti Holdings plc,…

Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A/Regulation S offering by MPH Acquisition Holdings LLC, a wholly owned subsidiary of MultiPlan…

Davis Polk advised Soltec Power Holdings, S.A. on the Rule 144A/Regulation S initial public offering by Soltec Power Holdings of 31,146,717 of its ordinary shares. The initial public…

Davis Polk advised Delek Overriding Royalty Leviathan Ltd., on its Rule 144A offering of $180 million principal amount of 7.494% senior secured notes due 2023. The notes are secured by…

Davis Polk advised the representatives of the several underwriters in connection with Abcam plc’s $180 million U.S. initial public offering of 10,287,000 American depositary shares…

Davis Polk advised Xspray Pharma AB (publ) on a private placing of new shares. The private placing raised gross proceeds of approximately SEK 265 million.  Xspray was founded in 2003…

Davis Polk advised Royalty Pharma plc and the selling shareholders on Royalty Pharma’s $728 million secondary offering of 17,343,037 of its Class A ordinary shares by certain selling…